---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-041538"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:51:12.195540+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# TriSalus reports 77% Q4 revenue growth but warns of late 10-K filing due to stock-comp errors

## Summary
- Q4 revenue $5.7M (+77% YoY); full year $18.5M (+49% YoY); gross margin improved to 90% and 86%.
- Operating loss Q4 $14.1M, full year $54.2M (incl. $7.9M deSPAC costs); net loss $35.5M and $59.0M.
- Basic/diluted EPS loss Q4 $1.56, full year $6.73 (vs. $75.01/$161.55 in 2022, impacted by deSPAC).
- Will file late 10-K due to stock-based compensation errors; results are unaudited and subject to change.
- CMS granted HCPCS code for TriNav; 510k clearance for TriNav Large and TriGuide; phase 1 trials enrollment completed.

## SEC filing metadata
- accession: 0001104659-24-041538
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/tm2410283d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-041538
- JSON: https://secwatch.observer/filing/0001104659-24-041538.json
- Plain text: https://secwatch.observer/filing/0001104659-24-041538.txt

## Key facts
- Earnings Releases
  TriSalus Life Sciences, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On April 1, 2024, TriSalus Life Sciences, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465924041538/0001104659-24-041538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.